RECRUITMENT OF A TOBY BABY

INTRODUCTION
TOBY is a randomised controlled trial comparing two methods of caring for infants with perinatal asphyxia. It compares intensive care including whole body cooling with standard intensive care. This handbook describes the practical aspects of the study. For a detailed description of the background to the study, the scientific aspects of the study and the analysis plan, please see the TOBY Study Protocol.
Overview of the study design
More information is available in later sections of this handbook and in the TOBY Study Protocol.
Eligibility and exclusions
Babies are eligible if they are born at term with evidence of perinatal asphyxia (see Section 2.1 for details of the eligibility criteria). They must be less than 6 hours old at the time they join the study.
Recruitment and randomisation
Eligible infants will be assigned either to "intensive care with cooling" or "intensive care" by a central telephone randomisation service.
Interventions and clinical management
Intensive care with cooling group: intensive care with whole body cooling, with rectal temperature maintained at 33.5 ± 0.5°C.
Intensive care group: neonatal intensive care with rectal temperature maintained at 37.0 ± 0.2°C.
Primary outcome
Combined incidence of mortality and severe neurodevelopmental disability in survivors at 18 months of age.
Secondary outcomes
These include measures of short-term complications and long-term disability. 
Co-ordination of the study
Local co-ordination
Each Treatment Centre (the hospitals where babies recruited to TOBY will be cared for) will maintain a rota of trained clinicians who will be available to deal with recruitment of babies in their hospital, requests for referrals from outlying hospitals and other aspects of the study at all times.
Infants that meet criteria A will be assessed for whether they meet the neurological abnormality entry criteria (B) by trained personnel:
B.
Moderate to severe encephalopathy, consisting of altered state of consciousness (lethargy, stupor or coma) AND at least one of the following: · hypotonia. · abnormal reflexes including oculomotor or pupillary abnormalities. · an absent or weak suck. · clinical seizures, as recorded by study personnel.
Infants that meet criteria A & B will be assessed by aEEG (read by trained personnel):
C.
At least 30 minutes duration of amplitude integrated EEG recording that shows abnormal background aEEG activity or seizures (see the CFM manual for information on interpretation of the aEEG). There must be one of the following: · normal background with some seizure activity. · moderately abnormal activity. · suppressed acitivity. · continuous seizure acitivity.
The aEEG may be performed from one hour of age. If subsequently an abnormal aEEG is recorded before 6 hours of age, the infant then becomes eligible for recruitment. (Information on interpretation of the aEEG is available on the following website: http:// www.azzopardi.freeserve.co.uk/CFM/interpretation_of_cfm.htm).
NOTE:
The aEEG should not be performed within 30 min of IV anticonvulsant therapy as this may cause suppression of EEG activity. In particular, high dose anticonvulsant therapy (e.g. >20mg/kg phenobarbitone) should not be given prior to performing the aEEG.
Exclusion criteria:
· Infants expected to be >6 hours of age at the time of randomisation. · Major congenital abnormalities, such as diaphragmatic hernia requiring ventilation, or congenital abnormalities suggestive of chromosomal anomaly or other syndromes that include brain dysgenesis.
NOTE: Every effort should be made to ensure entry to the study before 3 hours of age, because there may be rapid attenuation of neuroprotection with delay in the start of cooling. If the majority of infants in the study are recruited more than 3 hours after birth, any beneficial effect of cooling may be underestimated or not detected.
Infants will be recruited both from centres which provide the cooling treatment ("Treatment Centres"), and from outlying hospitals that refer to these hospitals. All babies recruited to the study, whether they are in the cooled or non-cooled group, will be cared for in Treatment Centres. All babies recruited to TOBY from referral hospitals will therefore be transferred to Treatment Centres.
Procedures for recruiting babies at Treatment Centres and referral centres are slightly different (See Section 2.3 and 2.4).
Consent
There are several stages to the consent process:
· Preliminary written information (Perinatal asphyxia and your baby) will be provided by the clinical team caring for the baby at birth if a cot is available at the Treatment Centre.
· More detailed information (both written (Parent Information Leaflet) and spoken) will be given by the transfer team or the attending team at the Treatment Centre, who will obtain written consent from the parent(s).
· Once a baby has been randomised into the study, information about the study should continue to be given as and when the parents request it. An appointment with the senior clinician responsible for the baby's care should be made as soon as possible, for the parents to discuss participation in detail. At this stage it should be made clear that the parents remain free to withdraw their baby from the study at any time but that if they do withdraw their baby, we would ask them for consent to continue follow up.
· A senior investigator will be available at all times to discuss concerns raised by parents or clinicians during the course of the study, for example (a) when parents or clinicians at a Treatment Centre wish to withdraw cooling for a baby allocated to this intervention (b) giving advice to clinicians who are asked by parents to provide cooling outside the trial (c) giving advice to parents who do not wish to participate in the study.
· Information about the study will continue for parents after their baby leaves the neonatal unit or dies. A regular newsletter will be produced giving parents up to date information about the study until it has finished. Experience with other studies in this area suggests that parents of babies who die may want to receive these newsletters, and all parents will be offered the opportunity to receive this information if they wish to.
Recruitment of babies born in Treatment Centres
The baby's condition should first be stabilised and then assessed for potential eligibility for TOBY. If the baby is considered eligible for TOBY on clinical grounds including the aEEG, the attending clinician should:
1.Inform the parents about the study and give the leaflet Perinatal asphyxia and your baby.
2.Inform the TOBY clinician, who will discuss the study with the parents in more detail and give them a more detailed and specific information leaflet (Parent Information Leaflet).
3.If the parents give consent for their baby to participate a Consent Form should be completed and signed by the parent(s).
4.If the TOBY clinician is not available, the most senior attending clinician can seek consent (this can be a specialist registrar who has received training about the study and the consent procedures from the Lead Investigator).
5.If consent is given, the baby can be randomised into the study (see Section 3).
6.Start the allocated treatment as soon as possible.
7.For babies who are not eligible for the study because of mild encephalopathy, a further information leaflet can be given to the parents by the attending clinician (Information for parents of babies with mild perinatal asphyxia).
Recruitment of babies born in referring hospitals
The baby's condition should first be stabilised and then assessed for potential eligibility for TOBY.
If the baby is considered eligible for TOBY on clinical grounds (criteria A and B; see Section 2.1) the attending clinician should:
1.Telephone the nearest Treatment Centre and discuss with the TOBY clinician whether they can accept the referral.
2.If the referral can be accepted, the local clinicians should inform the parents about the study and give them the leaflet Perinatal asphyxia and your baby. This leaflet contains basic information about perinatal asphyxial encephalopathy and the TOBY study.
When the retrieval team arrives, they will take the following steps:
1.The baby will be assessed for study eligibility, including performing the aEEG.
2.During the course of this assessment the study will be discussed with the parents in more detail with a slightly more detailed and specific information leaflet (Parent Information Leaflet).
3.If eligibility is confirmed, the parent(s) will be asked for consent for their baby to participate.
4.A Consent
Form should be completed and signed by the parent(s).
5.
The baby should then be randomised into the study (see Section 3).
6.The allocated treatment should be started at the referring hospital and the baby should be transferred to the Treatment Centre as soon as possible.
7.For babies who are not eligible for the study because they have mild encephalopathy, a further information leaflet can be left with the parents by the transfer team (Information for parents of babies with mild perinatal asphyxia).
Mild encephalopathy
The assessment of the baby at the referring hospital may not confirm eligibility (i.e. there is only mild encephalopathy). The CFM findings should be explained to the parents, and they should be given the parent information leaflet Information for parents of babies with mild perinatal asphyxia. In this situation the baby will remain at the referring hospital if this is the usual practice for this hospital. However, as transfer will have been mentioned to the parents during discussions about study participation, there may be a perception that transfer to the Treatment Centre may in itself be beneficial. The baby may be transferred if the parents request this.
Requests for cooling outside the study
Parents may decline study entry and request cooling for their baby. As the use of cooling is experimental, its use outside this study will not be permitted.
RANDOMISATION
When a baby's eligibility has been confirmed and the parent(s) have signed a consent form, the baby can be randomised into the study. This is achieved by telephoning the randomisation service (based at the National Perinatal Epidemiology Unit in Oxford).
Please follow these steps:
1.Complete the first page of the TOBY Entry Form.
2.Telephone the randomisation service (07623 947508). Leave the following message with the operator: "Please call <YOUR NAME> at <HOSPITAL NAME> on <TELEPHONE NUMBER> about TOBY." You will be called back immediately.
3.Record the baby's study number and allocation on the Entry Form.
4.Write the baby's study number on a TOBY Participation label and attach it to the front of the baby's notes 5.Commence the allocated treatment.
6.Once the baby is stabilised, complete the remainder of the Entry Form.
7.If the baby was born in a referring hospital, transfer the baby to the Treatment Centre.
8.Start recording the requested information about the baby on the Daily Log forms (use Day 1 to Day 4 in order).
9.Send the completed Entry Form to the TOBY Data Co-ordinating Centre using the FREEPOST envelope provided.
STUDY INTERVENTIONS
Intensive care group
Infants will be dried at birth, and kept warm during resuscitation. The infants will be cared for under an overhead radiant heater or in closed incubators. Rectal temperature should be maintained at 37.0°C ± 0.2°C. The rectal temperature will be recorded hourly on the Daily Log forms for the first 80 hours after randomisation.
Intensive care group with cooling
At the Treatment Centres, hypothermia is maintained using the Tecotherm cooling system, which induces hypothermia by circulating fluid within a special mattress. A temperature thermostat can be regulated to alter the temperature of the fluid. Typically the thermostat should be set at or around 25 -30 o C to achieve a target rectal temperature of 33 -34 o C.
Cooling for infants born in referring hospitals
For infants born in referring hospitals who are assigned to cooling, the intervention should be started immediately after randomisation. The infants are nursed prior to transfer with the overhead radiant warmer turned off. During transport the infant is nursed in a transport incubator. Heart rate and oxygen saturation and the rectal temperature should be monitored continuously and the incubator heater turned on and adjusted if necessary to maintain the rectal temperature between 33 and 34 o C. Cooled gel packs may be placed around the infant, if necessary, to maintain the target temperature. Blood pressure should be monitored either continuously if an intra-arterial catheter has been inserted or every 15 minutes by oscillometric technique until arrival at the Treatment Centre.
NOTE: Some referring hospitals may have quick access to a Treatment Centre. If it is likely that the infant can be transported to a study centre sufficiently quickly that cooling (if allocated) can be started within three hours of birth, assessment and randomisation may be postponed until admission to the Treatment Centre. These infants will receive the normal standard of care, including maintaining a rectal temperature of 37 +/-0.2 o C, during the transfer.
Rewarming procedures for infants allocated to cooling
When cooling is concluded (72 hours after randomisation, or earlier if clinical circumstances dictate) the rectal temperature should be allowed to rise by no more than 0.5°C per hour, to 37±0.2°C. The thermostat set point of the Tecotherm system can be adjusted as needed, to rewarm the infant. The infant's temperature must be carefully monitored for at least 4 hours to prevent rebound hyperthermia, as this might be detrimental.
Discontinuing cooling treatment
Cooling may be discontinued if the following occur: · Parents request that cooling be stopped prior to 72 hours after randomisation. This decision should be made in discussion with the TOBY clinician whenever possible. · Attending clinician stops cooling. Reasons for early discontinuation of cooling might include clinical, EEG and imaging evidence of severe, irreversible brain injury, or inability to maintain rectal temperature in the desired range. · Baby receives ECMO.
If the parents or the attending paediatrician elect to discontinue cooling, then rewarming will be commenced.
NOTE: Apparent improvement on continuous aEEG recording, after study entry, is not an indication for discontinuing cooling.
CLINICAL CARE
Treatment Centres will provide a uniform standard of clinical care for all babies in the study, to minimize potential bias that could arise from differential use of co-interventions.
Anti-oedema therapy
Infants in the study must not be treated with steroids or mannitol.
Analgesic and sedative therapy
Stress may have adverse effects in asphyxiated infants and may influence the therapeutic effect of hypothermia. In addition, neonatal intensive care procedures may cause considerable stress to infants and cooling may also be associated with stress. Signs of distress include tachycardia, facial grimacing and irritability. A heart rate consistently above 100 bpm in cooled infants strongly suggests that the infant is distressed. All ventilated infants should be sedated with intravenous morphine, loading dose 50 micrograms/kg over 30 minutes followed by 10-40 micrograms/kg/hour. Non-ventilated infants who appear distressed should be treated similarly. Respiratory function must be monitored on these babies.
Fluid Management
Renal function is commonly impaired following severe perinatal asphyxia. The infant's weight, blood creatinine and electrolytes and urine output will guide fluid management. As a guide infants will require about 40-60 ml/kg/ day. Infants in renal failure should receive a total of 30 ml/kg/24 hours plus any measured losses. Boluses of 0.9% saline may be required to avoid hypovolaemia if the infant develops diuresis or if vasodilatation occurs during rewarming. Oral feeds should not be given during 80 hours following randomisation to either treatment group.
Seizure therapy
Seizures, whether noted on a EEG or on clinical signs, will be treated with phenobarbitone 20mg/kg loading dose over 20 min IV repeated if necessary after 40-60 minutes, followed by 5-10 mg/kg/day. If seizures persist, intravenous midazolam 100 micrograms/kg followed by 30-100 micrograms/kg/hour may be added. Further anticonvulsant therapy, if required, should comply with the policy for each treatment centre.
Ventilation
Almost all study infants will initially require mechanical ventilation. Ventilatory care will be managed according to the Treatment Centre's standard policy and this may include treatment with high frequency oscillation and inhaled nitric oxide if necessary. Blood gases will guide ventilatory requirements; as a guide PaO 2 should be maintained between 6-10 KPa and the PaCO 2 between 5-7 KPa.
Cardiovascular support
Alterations in heart rate and blood pressure are common during hypothermia. In general the heart rate is reduced and blood pressure increases with a reduction in body temperature. Most infants with a rectal temperature of 33.5 o C (the target rectal temperature in the group randomized to receive hypothermia) will have a heart rate around 100 bpm and a mean blood pressure greater than 40 mmHg. A rapid rise in body temperature may cause hypotension by inducing peripheral vasodilatation. Causes of hypotension should be sought and appropriate treatment provided. For this study treatment with volume replacement and inotropes should be commenced if the mean arterial blood pressure is less than 40 mmHg. A bolus of 10-20 ml/kg of normal saline should be given initially, and repeated if necessary. If the blood pressure remains low following treatment with normal saline the infant should be treated with dopamine 5-10 micrograms/kg/min, and/or dobutamine 5-10 micrograms/kg/min. Persistent failure of response may be treated by increasing the dose of dopamine and dobutamine up to 20 micrograms/kg/min, followed by the addition of dexamethasone 250 micrograms/kg and/or adrenaline 0.1-1.5 micrograms/kg/min.
Sepsis
Antibiotic therapy may be given if clinically indicated.
DATA COLLECTION
Entry Form
The first part of the Entry Form should be completed after a baby has been assessed for eligibility, the study has been discussed with the parents and they have signed a consent form. The information on this part of the form will be needed when telephoning the randomisation service.
The baby's study number, the allocation and the time of study entry should be completed during the telephone call to the randomisation service.
The remainder of the Entry Form should be completed as soon as possible after randomisation, and the form should be sent to the TOBY Data Co-ordinating Centre immediately, using the FREEPOST envelopes provided.
Daily Log
The Daily Log should be completed every hour for the first 80 hours after randomisation. Some parameters will be recorded hourly, others less frequently. Individual requirements are specified on the form.
Discharge Form
A Discharge Form must be completed when a baby taking part in TOBY is discharged, transferred or dies. Only information relating to the baby's stay in your unit should be included on this form. If the baby is being transferred (see Section 8), the receiving hospital will complete another Discharge Form relating to the baby's stay in that unit.
A Going Home Pack containing a letter to the parents should be given to the family only when babies are discharged home.
Additional Items
a.Copy of CFM trace Please send a copy of the CFM trace to the co-ordinating centre, showing the eligibility assessment at least, and any other trace that has been obtained during the 80 hours of data collection.
b.Copies of US scans
Please print an extra set of scans so that one set can be sent to the co-ordinating centre. (See paragraph 7.1) c.Copy of MRI report Please provide a copy of the MRI report, whenever an MRI has been performed. (See paragraph 7.2) d.Death Summary Please provide a copy of the summary that is sent to the GP for babies that die before discharge.
NEUROIMAGING
Ultrasonography
Cerebral ultrasound should be performed within the first 24 hours after entry to the study and repeated every 24 hours until 80 hours after randomisation. Trained personnel should perform cerebral ultrasonography.
Standard views in coronal and sagittal planes, through the anterior fontanelle, can be supplemented with views through the posterior fontanelle and pterion, bilaterally, if considered necessary by the examiner. Examinations should be performed both at 5 and 7.5 MHz frequency.
Hard copies of all standard views should be retained for later review, which will be performed blinded to study group.
Magnetic Resonance Imaging
An MRI should be carried out if possible between 5-14 days after birth or prior to discharge if this is earlier. Images should be obtained in the transverse plane with T1 weighted spin echo, T2 weighted spin echo and age related inversion recovery sequences*, and assessed for abnormal signal intensities by an experienced observer, blinded to treatment category. Additionally, where possible, a set of sagittal T1 weighted volume images should also be acquired.
Normal anatomical features of the brain with no evidence of antenatal injury or malformation e.g. dilated ventricles, widened extra cerebral space or abnormal cortical folding, should be confirmed.
The pattern of abnormal signal intensities observed should be documented as follows:
· The posterior limb of the internal capsule (PLIC) assessed as normal, equivocal or abnormal · The basal ganglia and thalami assessed as normal, or with minimal, moderate or severe abnormality o Minimal: focal abnormalities but normal signal within the PLIC o Moderate: focal abnormalities involving the posterior lentiform nuclei and ventrolateral nuclei of the thalami with equivocal or abnormal signal intensity within the PLIC o Severe: widespread abnormalities in all regions of the basal ganglia and thalami and abnormal signal intensity within the PLIC.
· White matter abnormalities should be assessed according to which lobes of the brain are involved, whether there is a haemorrhagic element to the lesion and whether it is subcortical, periventricular or widespread. · Abnormalities in the white matter should be described as moderate or severe o Moderate: small focal lesions with a short T1 and short T2, consistent with haemorrhage and/or areas with an exaggerated long T1 and long T2 but no loss of grey/white matter differentiation. o Severe: more marked areas of abnormality with larger haemorrhages or exaggerated long T1 and T2 with loss of grey/white matter differentiation, consistent with infarction.
The presence of extra cerebral haemorrhage or collections should be noted, in particular evidence of subdural or large subarachnoid haemorrhage. Where possible the presence of normal flow in the sinuses should be confirmed and any thrombosis documented. The latter will require a set of both transverse and sagittal images.
A copy of the MRI report should be obtained from the radiologist.
* suggested sequences: · T1 weighted spin echo (SE 860/20) · T2 weighted spin echo (SE 300/120) · Inversion recovery (IR 3800/30/950) 20 8. TRANSFERS
Transfer of a baby recruited to TOBY from your unit
If a baby that is taking part in TOBY is transferred from your unit to another hospital, the TOBY Data Co-ordinating Centre will need to be informed so that all babies can be followed up until discharge from hospital or death. Please follow these procedures:
1.Complete the Discharge Form when the baby is transferred, filling in box 'b' (transferred to another hospital) in the Outcome section and giving as many details as possible about the receiving unit. Include only information about the baby's stay in your unit on this form. This form should be returned to the TOBY Data Co-ordinating Centre as soon as possible.
2.A Transfer Pack should accompany the baby to the receiving hospital. This contains a second discharge form, on which details of the baby's stay in the receiving hospital will be recorded.
3.Before the baby is transferred, fill in the baby's identifying details and TOBY study number on the Discharge Form in the Transfer Pack.
4.Send the Transfer Pack with the baby when it is transferred.
Transfer of a baby recruited to TOBY into your unit
A baby that has been recruited to TOBY may be transferred to your hospital. If this happens, the TOBY Data Co-ordinating Centre should have been informed by the transferring hospital, and a Transfer Pack should have been sent with the baby.
Please follow the following procedures:
1.Telephone the TOBY Data Co-ordinating centre to confirm that they have been informed about the baby's transfer.
2.The baby's identifying details and study number on the Discharge Form in the transfer pack should have been completed by the transferring hospital. If it has not been completed, please contact the TOBY Data Co-ordinating Centre.
3.When the baby is discharged home, dies or is transferred to another hospital, complete the Discharge Form. Include only information about the baby's stay in your unit on this form. Send the completed form to the TOBY Data Co-ordinating Centre as soon as possible.
4.If the baby is transferred please telephone the TOBY Data Coordinating Centre to inform them, so that a further Discharge Form can be supplied to the receiving hospital.
5.The Transfer Pack contains a Going Home Pack. This contains a letter to the parents, and should be given to the family only when a baby is discharged home.
SERIOUS ADVERSE EVENT REPORTING
If an UNEXPECTED serious adverse event occurs, it should be reported to the TOBY Data Co-ordinating Centre within 24 hours, using one of the Serious Adverse Event Report forms. The TOBY Data Co-ordinating Centre will ensure that the TOBY Data Monitoring and Ethics Committee and the Multicentre Research Ethics Committee are informed.
Serious adverse events that may be due to hypothermia are: · Cardiac arrhythmia. · Major venous thrombosis not related to an infusion line. · Severe hypotension (mean arterial pressure less than 25mmHg), despite full inotrope support and volume replacement.
